Bavarian Nordic Discloses Share Transactions Involving Management

COPENHAGEN, Denmark, September 4, 2026 /CourierPR/ -- Bavarian Nordic, a global vaccine company based in Denmark, has disclosed a series of share transactions involving its management and associated parties. The company, which specializes in the development and supply of vaccines for public health preparedness, including mpox and smallpox vaccines, reported these transactions in its latest announcement.

According to the company, the shares were traded by individuals holding managerial responsibilities and entities closely linked to these individuals. The transactions are part of ongoing business activities and do not represent any major changes in the company's operations or financial standing.

The information was provided by Anders Hjort, Head of Investor Relations at Bavarian Nordic, who stated, "These transactions are routine and are conducted in accordance with our internal policies and regulations."

Bavarian Nordic continues to focus on its mission to improve global health through innovative vaccines. The company's portfolio includes not only vaccines for public health emergencies but also travel vaccines, positioning it as a key player in both government and commercial markets.

For further details, interested parties can visit the company’s official website at www.bavarian-nordic.com.